Table of Contents Author Guidelines Submit a Manuscript
Tuberculosis Research and Treatment
Volume 2018, Article ID 7906846, 8 pages
https://doi.org/10.1155/2018/7906846
Research Article

Evaluating an Education Program to Reduce Indeterminate QuantiFERON Gold In-Tube Results

1Houston Methodist Research Institute, Department of Pathology and Genomic Medicine, 6670 Bertner Ave, Houston, TX 77030, USA
2Houston Methodist Hospital, Department of Quality, PI and Patient Safety, 6565 Fannin St, Houston, TX 77030, USA

Correspondence should be addressed to Edward A. Graviss; gro.tsidohtemnotsuoh@ssivargae

Received 16 July 2018; Revised 14 September 2018; Accepted 25 September 2018; Published 11 October 2018

Academic Editor: José R. Lapa e Silva

Copyright © 2018 Saroochi Agarwal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Stop TB Partnership, U., The Global Plan To End TB 2106-2020. 2015.
  2. P. M. Simone, “Essential Components of a Tuberculosis Prevention and Control Program: Recommendations of the Advisory Council for the Elimination of Tuberculosis,” Morbidity and Mortality Weekly Report: Recommendations and Reports, 1995, vi-16. View at Google Scholar
  3. Q. Inc, Ed., QuantiFERON-TB Gold package Insert, Germantown, MD, 2015.
  4. M. Tebruegge, H. De Graaf, P. Sukhtankar et al., “Extremes of age are associated with indeterminate QuantiFERON-TB gold assay results,” Journal of Clinical Microbiology, vol. 52, no. 7, pp. 2694–2697, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. U. Helwig, M. Müller, J. Hedderich, and S. Schreiber, “Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients,” Journal of Crohn's and Colitis, vol. 6, no. 4, pp. 419–424, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Sauzullo, F. Mengoni, R. Scrivo et al., “Evaluation of QuantiFERON-TB gold in-tube in human immunodeficiency virus infection and in patient candidates for anti-tumour necrosis factor-alpha treatment,” The International Journal of Tuberculosis and Lung Disease, vol. 14, no. 7, pp. 834–840, 2010. View at Google Scholar · View at Scopus
  7. M. C. Aichelburg, J. Tittes, F. Breitenecker, T. Reiberger, N. Kohrgruber, and A. Rieger, “Prognostic value of indeterminate IFN-γ release assay results in HIV-1 infection,” Journal of Clinical Microbiology, vol. 50, no. 8, pp. 2767–2769, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Papay, A. Eser, S. Winkler et al., “Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases,” European Journal of Clinical Investigation, vol. 41, no. 10, pp. 1071–1076, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Inoue, T. Nakamura, A. Katsuma et al., “The value of QuantiFERON®TB-Gold in the diagnosis of tuberculosis among dialysis patients,” Nephrology Dialysis Transplantation , vol. 24, no. 7, pp. 2252–2257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Fabre, S. Shoham, K. R. Page, and M. Shah, “High Proportion of Indeterminate QuantiFERON-TB Gold In-Tube Results in an Inpatient Population Is Related to Host Factors and Preanalytical Steps,” Open Forum Infectious Diseases, vol. 1, no. 2, 2014, ofu088. View at Google Scholar
  11. D.-H. P. Bui, A. T. Cruz, and E. A. Graviss, “Indeterminate QuantiFERON-TB gold in-tube assay results in children: Possible association with procedural specimen collection,” The Pediatric Infectious Disease Journal, vol. 33, no. 2, pp. 220–222, 2014. View at Publisher · View at Google Scholar · View at Scopus
  12. R. L. Gaur, M. Pai, and N. Banaei, “Impact of blood volume, tube shaking, and incubation time on reproducibility of Quantiferon-TB gold in-tube assay,” Journal of Clinical Microbiology, vol. 51, no. 11, pp. 3521–3526, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Herrera, E. Yeh, K. Murphy, J. Parsonnet, and N. Banaei, “Immediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay,” Journal of Clinical Microbiology, vol. 48, no. 8, pp. 2672–2676, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. D. Doberne, R. L. Gaur, and N. Banaei, “Preanalytical delay reduces sensitivity of quantiFERON-TB gold in-tube assay for detection of latent tuberculosis infection,” Journal of Clinical Microbiology, vol. 49, no. 8, pp. 3061–3064, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. Gnowee, QFT Instructional Video, http://us-tb.gnowee.net/videos.
  16. Qiagen, QuantiFERON-TB Gold Blood Collection and Handing Training Guide, Q. Inc, Ed., 2012.
  17. C. Yanda and N. Hyland, Tuberculosis Screening with QuantiFERON [Power Point slides], 2013, https://www.ndhealth.gov/HIV/Documents/LunchnLearn/TB%20Screening%20with%20Quantiferon%20-%20Nancy%20Heighland.pdf.
  18. G. Cumming, Understanding the new statistics: Effect sizes, confidence intervals, and meta-analysis, Routledge, 2013.
  19. K. M. Ward-Cook, C. Lehmann, L. Schoeff, and R. Williams, “Clinical diagnostic technology,” The total testing process, 2003. View at Google Scholar
  20. M. B. Dunning F, M. B. Dunning III, and F. T. Fischbach, Nurses' quick reference to common laboratory & diagnostic tests, 2011.
  21. C. Miranda, B. Yen-Lieberman, P. Terpeluk, J. W. Tomford, and S. Gordon, “Reducing the rates of indeterminate results of the QuantiFERON-TB Gold In-Tube test during routine preemployment screening for latent tuberculosis infection among healthcare personnel,” Infection Control and Hospital Epidemiology, vol. 30, no. 3, pp. 296–298, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. Inc, Ed., QuantiFERON®-TB Gold Plus (QFT®-Plus) ELISA Package Insert, Hilden, Germany, 2016.